You must be signed in to view this page
Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non–Small Cell Lung Cancer
Volume 8, Number 2 (Mar 2017)
https://doi.org/10.6004/jadpro.2017.8.2.7
